PMID- 7693339
OWN - NLM
STAT- MEDLINE
DCOM- 19931201
LR  - 20091119
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 53
IP  - 22
DP  - 1993 Nov 15
TI  - Met expression and sarcoma tumorigenicity.
PG  - 5355-60
AB  - The met protooncogene tyrosine kinase receptor (Met) and its ligand, hepatocyte 
      growth factor/scatter factor (HGF/SF), ordinarily constitute a paracrine 
      signaling system in which cells of mesenchymal origin produce the ligand, which 
      binds to the receptor that is predominantly expressed in cells of epithelial 
      origin. However, mouse NIH/3T3 fibroblasts overexpressing Met induce tumor 
      formation in nude mice via an autocrine mechanism (S. Rong et al., Mol. Cell. 
      Biol., 12: 5152-5158, 1992). In this study, we report that human cell lines 
      established from various sarcomas express high levels of activated Met receptor. 
      HGF/SF is also detected in the human sarcoma cell lines but at a reduced level 
      when compared to primary fibroblasts. These properties, high Met expression and 
      reduced ligand levels, are indistinguishable from the properties of NIH/3T3 tumor 
      explant cells overexpressing Met (S. Rong et al., Mol. Cell. Biol., 12: 
      5152-5158, 1992; S. Rong et al., Cell Growth & Differ., 4: 563-569, 1993). 
      Moreover, paraffin-embedded sections of primary tumors from human osteosarcomas, 
      chondrosarcomas, and leiomyosarcoma stain intensely for Met and/or HGF/SF and 
      display extensive tumor cell heterogeneity with regard to both paracrine and 
      autocrine stimulation. On the basis of these findings, we propose that Met-HGF/SF 
      autocrine signaling may contribute to the tumorigenic process in human sarcomas.
FAU - Rong, S
AU  - Rong S
AD  - ABL-Basic Research Program, National Cancer Institute, Frederick Cancer Research 
      and Development Center, Maryland 21702.
FAU - Jeffers, M
AU  - Jeffers M
FAU - Resau, J H
AU  - Resau JH
FAU - Tsarfaty, I
AU  - Tsarfaty I
FAU - Oskarsson, M
AU  - Oskarsson M
FAU - Vande Woude, G F
AU  - Vande Woude GF
LA  - eng
GR  - N01-CO-74101/CO/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (RNA, Neoplasm)
RN  - 63231-63-0 (RNA)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - 3T3 Cells/chemistry/metabolism
MH  - Animals
MH  - Hepatocyte Growth Factor/*analysis/metabolism
MH  - Humans
MH  - Mice
MH  - Proto-Oncogene Proteins/*analysis
MH  - Proto-Oncogene Proteins c-met
MH  - RNA/*analysis
MH  - RNA, Neoplasm/*analysis
MH  - Receptor Protein-Tyrosine Kinases/*analysis
MH  - Sarcoma/*chemistry/metabolism
MH  - Tumor Cells, Cultured
EDAT- 1993/11/15 00:00
MHDA- 1993/11/15 00:01
CRDT- 1993/11/15 00:00
PHST- 1993/11/15 00:00 [pubmed]
PHST- 1993/11/15 00:01 [medline]
PHST- 1993/11/15 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1993 Nov 15;53(22):5355-60.